Pharmaron Beijing Co., Ltd. (SHE:300759)

Pharmaron Beijing Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Revenue Revenue Growth	15,250	14,095	12,276	11,538	10,266	7,444
Revenue Growth	16.30%	14.82%	6.39%	12.39%	37.92%	45.00%
Gross Profit Gross Profit Growth	5,186	4,890	4,184	4,116	3,764	2,676
Operating Income Operating Income Growth	2,111	2,045	1,719	1,690	1,667	1,448
Net Income Net Income Growth	1,713	1,664	1,793	1,601	1,375	1,661
Earnings Per Share EPS Growth	0.95	0.94	1.01	0.90	0.77	0.91
EPS Growth	21.60%	-7.12%	12.13%	16.54%	-15.21%	38.94%

Revenue by Segment

Chart

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Laboratory Services (Excl. Macromolecule and Cell and Gene Therapy Services) Laboratory Services (Excl. Macromolecule and Cell and Gene Therapy Services) Growth	8,159	7,047	6,660	-	4,566
CMC (Small Molecule CDMO) Service CMC (Small Molecule CDMO) Service Growth	3,483	2,989	2,711	2,407	1,746
Clinical Development Services Clinical Development Services Growth	1,957	1,826	1,737	1,394	956.36
Others Others Growth	21.9	6.4	4.61	26.19	24.48
Biologics and CGT Services Biologics and CGT Services Growth	474.69	407.52	424.94	351.03	150.97
Total Total Growth	14,095	12,276	11,538	10,266	7,444

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Cash & Investments Cash & Investments Growth	2,452	2,617	3,062	6,693	2,856	6,178
Total Debt Total Debt Growth	6,954	7,040	5,975	9,698	6,117	5,285
Net Cash (Debt) Net Cash Growth	-4,501	-4,423	-2,913	-3,005	-3,260	893.04
Net Cash Growth	-	-	-	-	-	-68.12%
Net Cash Per Share Net Cash Per Share Growth	-2.50	-2.50	-1.64	-1.69	-1.84	0.49

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	2,897	3,221	2,577	2,754	2,143	2,058
Capital Expenditures CapEx Growth	-2,883	-2,669	-2,041	-2,865	-2,950	-2,093
Free Cash Flow Free Cash Flow Growth	14.16	551.97	536.02	-111.78	-807.04	-34.78
Free Cash Flow Growth	-97.79%	2.98%	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Gross Margin	34.01%	34.70%	34.09%	35.67%	36.67%	35.95%
Operating Margin	13.84%	14.51%	14.01%	14.64%	16.23%	19.45%
Pretax Margin	13.29%	13.57%	17.04%	15.93%	16.23%	25.67%
Profit Margin	11.23%	11.80%	14.61%	13.88%	13.39%	22.31%
FCF Margin	0.09%	3.92%	4.37%	-0.97%	-7.86%	-0.47%

Dividends

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 22, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Dividend Per Share Dividend Per Share Growth	0.200	0.200	0.200	0.200	0.200	0.200
Dividend Per Share Growth	0%	0%	0%	0%	0%	50.04%
Dividend Yield	0.39%	0.71%	0.79%	0.71%	0.46%	0.33%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 22, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
PE Ratio	50.48	28.34	23.33	29.59	55.98	64.05
Forward PE	32.42	24.72	26.22	25.72	35.75	59.23
P/FCF Ratio	5725.42	85.44	78.07	-	-	-
PS Ratio	5.32	3.35	3.41	4.11	7.50	14.29

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 22, 2026

Data Sources Report a data error